Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Anti MUC1 CAR-T cell and its preparation method and application

A technology of cells and lymphocytes, applied in the field of gene-modified cells and tumor treatment, to achieve the effect of high-efficiency tumor-killing activity

Active Publication Date: 2020-11-24
刘未斌
View PDF2 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

In addition to hematological tumors, researchers have been working hard to expand CAR-T therapy to solid tumors. However, CAR-T treatment of solid tumors is still in its early stages, and there are still many problems to be solved

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Anti MUC1 CAR-T cell and its preparation method and application
  • Anti MUC1 CAR-T cell and its preparation method and application
  • Anti MUC1 CAR-T cell and its preparation method and application

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0043] Preparation of Anti MUC1 CAR-T cells of the present invention

[0044] 1. Construction of lentiviral expression vector

[0045] Through conventional genetic engineering methods, the SCFV-IgD-CD28-OX40-CD3ζ fusion protein gene sequence was synthesized, and the SCFV-IgD-CD28-OX40-CD3ζ fusion protein gene sequence was cloned into a lentiviral expression vector to obtain SCFV-IgD-CD28 –OX40–CD3ζ lentiviral expression vector pGreen puro-CAR. Wherein, each sequence of the SCFV-IgD-CD28-OX40-CD3ζ fusion protein is as described above.

[0046] 2. Lentiviral packaging

[0047] 1) Culture 293T cells in 1640 medium with a mass fraction of 10 wt% fetal bovine serum (fetal bovine serum, FBS for short);

[0048] 2) 293T cells were treated with 3x 10 5 / cm 2 Transfer the density to a culture dish with a diameter of 15cm and cultivate it for 20h to ensure that the cell confluence is 80-90% during transfection;

[0049] Replace the medium with serum-free 1640 medium and set aside;...

Embodiment 2

[0063] The in vitro anti-tumor effect of the Anti MUC1 CAR-T cells prepared in Example 1 was evaluated, including the following steps:

[0064] With breast cancer cell line MCF-7 and pancreatic cancer cell line BxPC-3 stably expressing MUC1 as target cells, T cells infected with lentiviral vector pGreen puro-CAR (i.e., Anti MUC1 CAR-T cells prepared in Example 1 cells) and uninfected T cells to make effector cells, target cells according to the density of 1x 10 5 cells / ml inoculated in 96-well plate, 100 μl per well, added effector cells to target cells according to 5:1, 10:1, 20:1 effect-to-target ratio, placed in 5% CO 2 , cultured in a 37°C incubator for 4 hours, using WST-1 to detect cell viability, and calculate the killing efficiency.

[0065] figure 2 It is a schematic diagram of the killing effect of Anti MUC1 CAR-T cells and uninfected T cells on the target cell MCF-7 (breast cancer) according to the embodiment of the present invention; image 3 It is a schematic ...

Embodiment 3

[0068] The anti-tumor effect of the Anti MUC1 CAR-T cells prepared in Example 1 was evaluated in vivo, including the following steps:

[0069] Take 15 6-week-old female nude mice and inject 5x 10 subcutaneously in the right armpit 6 MCF-7 (breast cancer) cells, when the tumor grows to 60mm 3 Size, tumor model was randomly divided into 3 groups: control group, Anti MUC1 CAR-T cell group, T cell group; control group was injected with normal saline 200ul / time, twice a week; Anti MUC1 CAR-T cell group was injected with tail vein Anti MUC1 CAR-T cells 1×10 7 T cells / time, 2 times a week; T cells in the T cell group were injected into the tail vein 1×10 7 Each time, twice a week; the survival status of the mice within 100 days was counted, and the survival rate curve was made. Figure 4 It is a schematic diagram of the survival period of mice treated with breast cancer (MCF-7) xenografted tumor model mice by the Anti MUC1 CAR-T cells of the embodiment of the present invention, th...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention provides an Anti-MUC1 CAR-T cell and its preparation method and application. The Anti-MUC1 CAR-T cell expresses a SCFV-IgD-CD28-OX40-CD3 zeta fusion protein in the T cell. In the SCFV-IgD-CD28-OX40-CD3 zeta fusion protein, the SCFV is used to bind to the MUC1 protein. The amino acid sequence of SCFV is a first sequence. The cell is obtained by ornament and modification of the T cell, can specifically recognize and kill adenocarcinoma and is suitable for prevention and treatment on the corresponding tumor diseases.

Description

technical field [0001] The invention relates to an Anti MUC1 CAR-T cell and its preparation method and application, belonging to the technical field of gene modified cells and tumor treatment. Background technique [0002] In tumor immunotherapy methods, lymphocyte immune technology, including cytokine-induced killer cells, cytotoxic T lymphocytes and infiltrating T lymphocytes, has been used in clinical treatment of malignant tumors at home and abroad, and has achieved some clinical curative effects, but it is not Non-specific immune effect, due to the immune escape of tumor cells themselves and the concealment of antigens, it is still very limited in eliminating tumor cells in vivo. The emergence of chimeric antigen receptor genetically modified lymphocyte technology provides a new direction for clinical treatment of cancer. Chimeric antigen receptor T cell (Chimeric antigen receptor T cell, referred to as: CAR-T cell) therapy is to extract T lymphocytes from patients, un...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): C12N5/10C12N15/867C12N15/62A61K35/17A61P35/00
CPCA61K35/17C07K14/7051C07K14/70521C07K2317/622C07K2319/02C07K2319/33C12N5/0636C12N15/86C12N2510/00C12N2740/15043
Inventor 刘未斌
Owner 刘未斌
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com